PTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($2.78), $1.48 worse than the analyst estimate of ($1.30).

"We are pleased with the progress in our pipeline and the strong commercial performance of our global Duchenne franchise," said Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics. "Our growing revenue stream allows us to continue to invest in the development of treatments leveraging our novel technology platforms. We have a robust pipeline and with more than $1 billion in cash are well positioned to advance multiple differentiated therapies for patients living with rare disorders, not only in the near term, but also for many years to come."

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.